S Vordenbäumen1, R Brinks2, O Sander2, G Chehab2, G Lozitiello-Kiroudis2, H Acar2, J Richter2, R Fischer-Betz2, M Schneider2. 1. Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland. stefan.vordenbaeumen@med.uni-duesseldorf.de. 2. Medizinische Fakultät, Poliklinik und Funktionsbereich Rheumatologie & Hiller-Forschungszentrum Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Merowingerplatz 1a, 40225, Düsseldorf, Deutschland.
Abstract
BACKGROUND: Improvement of health-related quality of life (HRQoL) is a prioritized treatment target in systemic lupus erythematosus (SLE). A retrospective chart review of patients with repeated HRQoL measurements from the outpatient department was conducted in order to better understand which factors drive HRQoL in established SLE. Of particular interest was the association between HRQoL and disease activity. METHODS: The medical outcomes study short form 36 (SF-36), systemic lupus activity measure (SLAM) and routine clinical data of 169 patients (83% female, mean age 40.3 ± 13 years, disease duration 9.4 ± 7 years) over an average of 7.1 ± 4.2 years were available for analysis by linear mixed modelling. Factors associated with the physical component summary (PCS) and mental component summary (MCS) of the SF-36 were assessed. The proportion of HRQoL which could be explained by the variables was estimated by marginal R2 (mR2) and conditional R2 (cR2). RESULTS: At baseline, SLE patients showed a reduced HRQoL in all subscales of the SF-36 including PCS and MCS with the exception of vitality. A higher PCS over time was significantly associated with concurrent parameters, such as intake of antimalarial drugs, no glucocorticoid use, less fatigue, lower disease activity as well as to the baseline parameters of younger age and higher PCS (mR2 54.7%, cR2 59.9%). A higher MCS was associated with concurrent use of glucocorticoids and a higher baseline MCS (mR2 21.7%, cR2 25.1%). CONCLUSION: The use of antimalarial drugs and no glucocorticoid intake as well as low current disease activity are modifiable factors associated with a better physical HRQoL. The mental component of HRQoL was poorly represented by conventional parameters and not associated with parameters of disease activity in the present study cohort.
BACKGROUND: Improvement of health-related quality of life (HRQoL) is a prioritized treatment target in systemic lupus erythematosus (SLE). A retrospective chart review of patients with repeated HRQoL measurements from the outpatient department was conducted in order to better understand which factors drive HRQoL in established SLE. Of particular interest was the association between HRQoL and disease activity. METHODS: The medical outcomes study short form 36 (SF-36), systemic lupus activity measure (SLAM) and routine clinical data of 169 patients (83% female, mean age 40.3 ± 13 years, disease duration 9.4 ± 7 years) over an average of 7.1 ± 4.2 years were available for analysis by linear mixed modelling. Factors associated with the physical component summary (PCS) and mental component summary (MCS) of the SF-36 were assessed. The proportion of HRQoL which could be explained by the variables was estimated by marginal R2 (mR2) and conditional R2 (cR2). RESULTS: At baseline, SLEpatients showed a reduced HRQoL in all subscales of the SF-36 including PCS and MCS with the exception of vitality. A higher PCS over time was significantly associated with concurrent parameters, such as intake of antimalarial drugs, no glucocorticoid use, less fatigue, lower disease activity as well as to the baseline parameters of younger age and higher PCS (mR2 54.7%, cR2 59.9%). A higher MCS was associated with concurrent use of glucocorticoids and a higher baseline MCS (mR2 21.7%, cR2 25.1%). CONCLUSION: The use of antimalarial drugs and no glucocorticoid intake as well as low current disease activity are modifiable factors associated with a better physical HRQoL. The mental component of HRQoL was poorly represented by conventional parameters and not associated with parameters of disease activity in the present study cohort.
Authors: George Bertsias; Dimitrios T Boumpas; Antonis Fanouriakis; Myrto Kostopoulou; Alessia Alunno; Martin Aringer; Ingeborg Bajema; John N Boletis; Ricard Cervera; Andrea Doria; Caroline Gordon; Marcello Govoni; Frédéric Houssiau; David Jayne; Marios Kouloumas; Annegret Kuhn; Janni L Larsen; Kirsten Lerstrøm; Gabriella Moroni; Marta Mosca; Matthias Schneider; Josef S Smolen; Elisabet Svenungsson; Vladimir Tesar; Angela Tincani; Anne Troldborg; Ronald van Vollenhoven; Jörg Wenzel Journal: Ann Rheum Dis Date: 2019-03-29 Impact factor: 19.103
Authors: Ioannis Parodis; Angie H Lopez Benavides; Agneta Zickert; Susanne Pettersson; Sonia Möller; Elisabet Welin Henriksson; Anne Voss; Iva Gunnarsson Journal: Arthritis Care Res (Hoboken) Date: 2019-06 Impact factor: 4.794
Authors: Ronald F van Vollenhoven; Marta Mosca; George Bertsias; David Isenberg; Annegret Kuhn; Kirsten Lerstrøm; Martin Aringer; Hendrika Bootsma; Dimitrios Boumpas; Ian N Bruce; Ricard Cervera; Ann Clarke; Nathalie Costedoat-Chalumeau; László Czirják; Ronald Derksen; Thomas Dörner; Caroline Gordon; Winfried Graninger; Frédéric Houssiau; Murat Inanc; Søren Jacobsen; David Jayne; Anna Jedryka-Goral; Adrian Levitsky; Roger Levy; Xavier Mariette; Eric Morand; Sandra Navarra; Irmgard Neumann; Anisur Rahman; Jozef Rovensky; Josef Smolen; Carlos Vasconcelos; Alexandre Voskuyl; Anne Voss; Helena Zakharova; Asad Zoma; Matthias Schneider Journal: Ann Rheum Dis Date: 2014-04-16 Impact factor: 19.103
Authors: Chiara Tani; Elena Elefante; Viola Signorini; Dina Zucchi; Valentina Lorenzoni; Linda Carli; Chiara Stagnaro; Francesco Ferro; Marta Mosca Journal: RMD Open Date: 2019-06-11
Authors: Guillermo A Guaracha-Basáñez; Irazú Contreras-Yáñez; Gabriela Hernández-Molina; Viviana A Estrada-González; Lexli D Pacheco-Santiago; Salvador S Valverde-Hernández; José Roberto Galindo-Donaire; Ingris Peláez-Ballestas; Virginia Pascual-Ramos Journal: PLoS One Date: 2022-01-18 Impact factor: 3.240